Profile data is unavailable for this security.
About the company
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
- Revenue in USD (TTM)0.00
- Net income in USD-54.42m
- Incorporated2020
- Employees50.00
- LocationLongboard Pharmaceuticals Inc4275 Executive Square, Suite 950LA JOLLA 92037United StatesUSA
- Phone+1 (619) 592-9775
- Fax+1 (302) 636-5454
- Websitehttps://www.longboardpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nurix Therapeutics Inc | 80.89m | -144.73m | 754.94m | 284.00 | -- | 3.71 | -- | 9.33 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Y-mAbs Therapeutics Inc | 84.82m | -21.43m | 755.16m | 100.00 | -- | 7.46 | -- | 8.90 | -0.4909 | -0.4909 | 1.94 | 2.31 | 0.6299 | 1.93 | 4.85 | 848,190.00 | -15.91 | -44.23 | -19.40 | -50.45 | 86.60 | -- | -25.26 | -181.13 | 5.27 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 0.00 | -292.19m | 788.37m | 168.00 | -- | 1.80 | -- | -- | -4.56 | -4.56 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -50.65 | -47.40 | -57.28 | -54.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| SAGE Therapeutics Inc | 91.06m | -503.14m | 788.69m | 487.00 | -- | 1.12 | -- | 8.66 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Pliant Therapeutics Inc | 1.58m | -161.34m | 799.22m | 158.00 | -- | 1.68 | -- | 505.84 | -2.75 | -2.75 | 0.0269 | 7.90 | 0.0037 | -- | 1.59 | 10,000.00 | -37.40 | -33.24 | -39.82 | -35.39 | -- | -- | -10,211.14 | -360.29 | -- | -- | 0.0208 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Nuvation Bio Inc | 0.00 | -75.80m | 806.68m | 51.00 | -- | 1.18 | -- | -- | -0.3463 | -0.3463 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -11.72 | -16.27 | -11.97 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
| Tango Therapeutics Inc | 36.53m | -101.74m | 809.99m | 140.00 | -- | 3.06 | -- | 22.18 | -1.08 | -1.08 | 0.3865 | 2.48 | 0.0871 | -- | 36.53 | 260,907.10 | -24.25 | -- | -27.59 | -- | -- | -- | -278.54 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| SS Innovations International Inc | 5.88m | -20.94m | 810.94m | 239.00 | -- | 56.71 | -- | 137.92 | -0.1293 | -0.1293 | 0.04 | 0.0838 | 0.3939 | -- | 2.53 | 24,601.30 | -140.31 | -161.38 | -253.40 | -449.76 | 12.13 | -79.79 | -356.17 | -495.77 | 1.30 | -52.51 | 0.2963 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| Evolus Inc | 202.09m | -61.69m | 811.37m | 273.00 | -- | -- | -- | 4.02 | -1.08 | -1.08 | 3.55 | -0.3578 | 1.10 | 4.12 | 7.63 | 740,238.10 | -33.62 | -40.92 | -45.33 | -59.74 | 69.54 | 65.43 | -30.52 | -80.46 | 2.10 | -3.47 | 1.21 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Regenxbio Inc | 90.24m | -263.49m | 816.07m | 344.00 | -- | 2.35 | -- | 9.04 | -6.03 | -6.03 | 2.06 | 7.08 | 0.1283 | -- | 3.41 | 262,331.40 | -37.45 | -16.75 | -45.96 | -19.08 | 58.76 | 78.27 | -291.99 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -54.42m | 821.80m | 50.00 | -- | 13.67 | -- | -- | -2.39 | -2.39 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -89.72 | -- | -105.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -98.15m | 825.17m | 116.00 | -- | 2.13 | -- | -- | -2.37 | -2.37 | 0.00 | 9.84 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| National Research Corporation | 148.58m | 30.96m | 834.79m | 435.00 | 27.85 | 17.30 | 22.64 | 5.62 | 1.26 | 1.26 | 6.02 | 2.02 | 1.18 | -- | 11.00 | 341,563.20 | 24.49 | 26.25 | 33.80 | 36.77 | 62.30 | 63.20 | 20.84 | 23.95 | -- | 1,929.64 | 0.4286 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
| ALX Oncology Holdings Inc | 0.00 | -160.81m | 839.29m | 72.00 | -- | 4.38 | -- | -- | -3.74 | -3.74 | 0.00 | 3.80 | 0.00 | -- | -- | 0.00 | -58.58 | -34.34 | -66.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0592 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| 89bio Inc | 0.00 | -142.19m | 843.69m | 70.00 | -- | 1.54 | -- | -- | -2.01 | -2.01 | 0.00 | 5.75 | 0.00 | -- | -- | 0.00 | -35.86 | -45.50 | -38.49 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0442 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
Data as of May 03 2024. Currency figures normalised to Longboard Pharmaceuticals Inc's reporting currency: US Dollar USD
43.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 02 Jan 2024 | 3.07m | 9.15% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 2.35m | 7.00% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 1.65m | 4.91% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 1.62m | 4.83% |
| Farallon Capital Management LLCas of 31 Dec 2023 | 1.56m | 4.65% |
| Polar Capital LLPas of 31 Dec 2023 | 1.00m | 2.98% |
| Ikarian Capital LLCas of 31 Dec 2023 | 979.46k | 2.92% |
| Integral Health Asset Management LLCas of 31 Dec 2023 | 900.00k | 2.68% |
| Point72 Asset Management LPas of 31 Dec 2023 | 825.00k | 2.46% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 793.55k | 2.36% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
